In a recent episode of the talk show The View, Joy Behar, the 83-year-old Emmy Award-winning comedian, candidly shared how her taste preferences have dramatically altered since her experience with Ozempic, a medication that has helped her shed 25 pounds. The discussion arose during a segment that spotlighted a new study indicating that lobsters can experience pain when plunged into boiling water.
:max_bytes(150000):strip_icc():format(jpeg)/Joy-Behar-041626-f6df8d9429f246edb72305c85bc25888.jpg)
Behar expressed a strong aversion to seafood, stating, “Ever since I went on Ozempic, I lost like 25 lbs., I cannot eat seafood anymore. I can’t. Dead or alive, I’m not eating them.” Her remarks echoed the sentiments of many individuals navigating dietary changes influenced by obesity treatments. “I can’t look at shrimp, I can’t look at fluke, nothing,” she added, clearly disturbed by the mere thought of consuming seafood.
Fellow co-host Whoopi Goldberg contributed her own seafood-related anxieties to the conversation. Goldberg mentioned her discomfort with shrimp that still retain their heads, stating, “I don’t want anything like this looking at me.” She recounted a particularly unsettling experience involving a lobster that had not finished cooking and “moved” while being prepared, an incident that has deterred her from eating lobster ever since.
The episode highlighted a growing awareness and discussion around GLP-1 medications, such as Ozempic and Mounjaro, which are primarily used to manage blood sugar levels and facilitate weight loss. Behar, along with her co-hosts, discussed their personal journeys with these medications, contributing to a broader narrative surrounding their popularity and effects on lifestyle choices.
In a previous episode from February, Behar expressed pride in her weight loss achievements, evoking a supportive camaraderie among her co-hosts. “We all did it!” she exclaimed, referring to the collective success they experienced through their use of GLP-1 medications. Whoopi Goldberg notably stated, “I did it because I was almost 300 lbs. and I’m looking good now!”
Savannah Chrisley, a guest co-host on The View, also shared her successful journey with GLP-1 drugs, revealing that she had lost 40 pounds. This candid discussion has endeared the talk show to many viewers, who appreciate the unfiltered honesty about the challenges and triumphs faced in their weight loss journeys.
Sunny Hostin, another co-host, also unveiled her personal experience during the same conversation in 2024, noting her weight gain of 40 pounds during the COVID-19 pandemic. “All I did was eat… I love to cook, and I found out, I love to eat,” she said. Hostin mentioned that she resorted to Mounjaro to aid her in managing her weight, underlining the shifting attitudes towards weight management through medication.
The discussions on The View indicate a growing acceptance and exploration of GLP-1 medications, which have shown to effectively aid in weight loss. According to a study published in 2025 in the journal Diabetes, Obesity, and Metabolism, these medications also impact users’ taste perception, which may explain why Behar and her co-hosts have developed aversions to foods they once enjoyed.
As public awareness of GLP-1 drugs expands, so too does curiosity about their potential effects on dietary choices and general wellness. The conversations on The View serve as an important reminder of the complexities surrounding weight loss and the individual experiences that come with modern medications.
The reactions from Behar, Goldberg, Hostin, and Chrisley underscore the multifaceted impacts these drugs can have, extending beyond physical appearance to affect personal tastes and culinary preferences. As more people consider these options for weight management, discussions like those seen on The View will continue to be vital in shaping the narrative around obesity treatments and their broader implications on lifestyle.
Ultimately, Behar’s shifting tastes represent just one example of the nuanced changes occurring within the realm of health and diet as more individuals navigate their relationships with food through the lens of modern medicinal interventions.